Tern highlights IoT innovation in portfolio company presentations

Tern plc

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IoT) technology businesses, is pleased to announce that following a well-attended online presentation and a Q&A session yesterday evening involving Tern’s portfolio companies Device Authority, FundamentalVR, Talking Medicines and Vortex IQ (a Sure Valley Enterprise Capital Fund (SVV2) portfolio company), copies of the presentations from the participating companies can be found via the links below:

Tern Plc is using its experience in pioneering leading-edge tech combined with a deep reach into expanding world markets to unlock the potential of UK companies who may be starting local, but are dreaming global. 

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern increases convertible loan note investment in Talking Medicines

Tern has received £270,000 of new unsecured convertible loan notes from Talking Medicines, increasing its total convertible loan note holding to approximately £0.79 million while retaining a 23.8% equity stake.

Tern Plc invests $280,000 in Device Authority convertible loan notes

Tern has invested $280,000 in new unsecured convertible loan notes issued by Device Authority, forming part of a wider funding round of up to $1.6 million from existing investors.

Surgical training technology moves closer to the centre of precision medicine

Fundamental XR is targeting a critical adoption gap in advanced healthcare by using immersive simulation to help surgical teams prepare for complex procedures with greater consistency and scale.

GLP-1 therapies move into a wider investor debate

GLP-1 therapies are moving beyond weight loss and diabetes, creating a wider investor discussion around behaviour, risk and market positioning.

Tern raises £222,000 through share placing

Tern has raised £222,000 before expenses through a placing of 37 million new ordinary shares at 0.60 pence per share, with admission to AIM expected on or around 22 May 2026.

FundamentalXR targets surgical readiness for advanced eye therapies

FundamentalXR is targeting surgical readiness for advanced eye therapies with immersive simulation designed to support real-world adoption.

Search